Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-23
2010-06-29
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
07745144
ABSTRACT:
The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1is selected from the group consisting of N, Q, D and S; X2is selected from the group consisting of V, I and L; X1is selected from the group consisting of R and K; and X4is selected from the group consisting of V, I, L and F; R1is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1integrin to an extracellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting α3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.
REFERENCES:
patent: 5696229 (1997-12-01), Laurie et al.
patent: 5770563 (1998-06-01), Roberts et al.
patent: 5776892 (1998-07-01), Counts et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5789184 (1998-08-01), Fowlkes et al.
patent: 6020312 (2000-02-01), Edwards
patent: 6689363 (2004-02-01), Sette et al.
patent: 10-257896 (1998-09-01), None
patent: WO 90/03983 (1990-04-01), None
patent: WO 92/09628 (1992-06-01), None
patent: WO 9420127 (1994-09-01), None
patent: WO 98/42737 (1998-10-01), None
Clezardin et al. Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. Biochem J. 321:819-827, 1997.
Kuntz. Structure-based strategies for drug design and discovery. Science. 1992 257(5073):1078-1082.
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 1997;6(10):2166-79.
Chandrasekaran, S., et al., “Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98,”Journal of Biological Chemistry, vol. 274(16), pp. 11408-11416 (Apr. 16, 1999).
Kahn, F., et al., “Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression,”Journal of Biological Chemistry, vol. 272(13), pp. 8270-8275 (1997).
Krutzsch, H., et al., “Identification of an alpha3beta1 integrin recognition sequence in thrombospondin-1,”Journal of Biological Chemistry, vol. 274(34), pp. 24080-24086 (Aug 20, 1999).
Li, C., et al., “An all-D amino acid peptide model of alphal(IV)531-543 from type IV collagen binds the alpha3betal integrin and mediates tumor cell adhesion, spreading, and motility,”Biochemistry, vol. 36(49), pp. 15404-15410 (Dec. 9, 1997).
Miles, A., et al., “Promotion of cell adhesion by single-stranded and triple-helical peptide models of basement membrane collagen α1 (IV)531-543: Evidence for conformationally dependent and conformationally independent type IV collagen cell adhesion sites,”Journal of Biological Chemistry, vol. 269(49), pp. 30939-30945 (Dec. 1994).
Nomizu, M., et al., “Identification of cell binding sequences in mouse laminin gammal chain by systematic peptide screening,”Journal of Biological Chemistry, vol. 272(51), pp. 32198-32205 (Dec. 19, 1997).
Prater, et al., “The properdin-like type I repeats of human thrombospondin contain a cell attachment site,”J. Cell Biol., vol. 112(5), pp. 1031-1040 (1991).
Krutzsch Henry C.
Roberts David D.
Haddad Maher M
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Peptides and their utility in modulation of behavior of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and their utility in modulation of behavior of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and their utility in modulation of behavior of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236978